Ken Griffin Dyadic International Inc Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Dyadic International Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 13,000 shares of DYAI stock, worth $12,220. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,000

Holding current value

$12,220

% of portfolio

0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.04 - $1.55 $2,149 - $3,203	2,067 Added 35.37%	7,911 $8,000
Q2 2024 Aug 14, 2024	SELL	$1.39 - $2.27 $5,151 - $8,412	-3,706 Reduced 38.81%	5,844 $8,000
Q1 2024 May 15, 2024	SELL	$1.29 - $1.67 $44,943 - $58,182	-34,840 Reduced 78.49%	9,550 $15,000
Q4 2023 Feb 14, 2024	BUY	$1.52 - $2.04 $18,308 - $24,571	12,045 Added 37.24%	44,390 $71,000
Q3 2023 Nov 14, 2023	SELL	$1.71 - $2.08 $53,104 - $64,594	-31,055 Reduced 48.98%	32,345 $62,000
Q2 2023 Aug 14, 2023	BUY	$1.56 - $2.38 $47,945 - $73,146	30,734 Added 94.09%	63,400 $122,000
Q1 2023 May 15, 2023	BUY	$1.25 - $1.86 $3,228 - $4,804	2,583 Added 8.59%	32,666 $58,000
Q4 2022 Feb 14, 2023	SELL	$1.18 - $2.32 $3,547 - $6,973	-3,006 Reduced 9.08%	30,083 $37,000
Q3 2022 Nov 14, 2022	SELL	$1.65 - $3.42 $30,221 - $62,640	-18,316 Reduced 35.63%	33,089 $63,000
Q2 2022 Aug 15, 2022	BUY	$1.85 - $3.22 $68,157 - $118,631	36,842 Added 252.98%	51,405 $157,000
Q1 2022 May 16, 2022	SELL	$3.01 - $4.81 $11,820 - $18,888	-3,927 Reduced 21.24%	14,563 $44,000
Q3 2021 Nov 15, 2021	BUY	$3.3 - $6.49 $458 - $902	139 Added 0.76%	18,490 $103,000
Q4 2020 Feb 16, 2021	BUY	$5.35 - $7.77 $98,177 - $142,587	18,351 New	18,351 $99,000

Others Institutions Holding DYAI

# of Institutions

Shares Held

5.06M

Call Options Held

13K

Put Options Held

500

View Full List

About DYADIC INTERNATIONAL INC

Ticker DYAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,423,100
Market Cap $26.7M
Description
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vac...

More about DYAI

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account